Thursday, November 21, 2024
11/21/2024
Summary The Mesenchymal Stromal Cell (MSC) Secretome Study is designed to assess the safety of allogeneic bone marrow-derived MSC secreted factors on the ocular surface, and also obtain a preliminary observation on 1) epithelial healing; 2) development of scarring; and 3) final visual acuity; with the objective of improving clinical outcomes in significant non-healing corneal epithelial disease. To achieve these goals, the MSC Secretome Study will include a Phase 1 safety and maximum tolerated dose study (Specific Aim #1) and a Phase 2a double- masked vehicle-controlled study to assess preliminary evidence of efficacy while identifying patient subgroups most likely to benefit from the treatment (Specific Aim#2).
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
